Targeted Study of Bufalin-mPEG-PLGA-PLL-cRGD on Colorectal Cancer in Nude Mice

Hu Songjiao,Wang Yan,Qiu Yanyan,Liang Bo,Liu Peifeng,Duan Yourong,Peng Wen,Yin Peihao,Qiu Ming,Li Qi
DOI: https://doi.org/10.3969/j.issn.1673-548X.2013.07.017
2013-01-01
Abstract:Objective To investigate the in vivo targeting efficacy of nanoparticles(NPs) made of methoxy polyethylene glycol(mPEG),polylactic-co-glycolic acid(PLGA),poly-l-lysine(PLL),and cyclic arginine-glycine-aspartic acid(cRGD) loaded with bufalin(bufalin-mPEG-PLGA-PLL-cRGD NPs),and to provide experimental evidence and method for the application of bufalin to treat colon cancer.Methods The mice were classified into 2 groups on the basis of the nanoparticles that they were administered: Dir-bufalin-mPEG-PLGA-PLL-cRGD NPs group and Dir-bufalin-of mPEG-of PLGA-PLL-cRGD NPs group,by injection through the vena caudalis one time in the experience.Fluorescence imaging of the tumor bearing mice was performed at 3 and 19h after injection by using a small animal in vivo fluorescence imaging system.Results Compared with the Dir-bufalin-mPEG-PLGA-PLL nanoparticles,the tumor fluorescence intensity of the mice treated with Dir-mPEG-PLGA-PLL-cRGD NPs was relatively stronger and lasted longer at 3h and 19h post-injection.Conclusion The Dir-bufalin-mPEG-PLGA-PLL-cRGD nanoparticles resulted in better tumor targeting and longer residue time in vivo.The experimental data show that the nanoparticles can help to improve the treatment effect of colorectal cancer.
What problem does this paper attempt to address?